Home
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial Setmelanotide Demonstrating Positive Efficacy Signal in Prader-Willi Syndrome

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial Setmelanotide Demonstrating Positive Efficacy Signal in Prader-Willi Syndrome

Today’s Highlights December 11, 2025

Rhythm Pharmaceuticals

Today, Rhythm Pharmaceuticals, Inc. (RYTM), announced positive preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS).

The firm also announced plans to advance setmelanotide into a Phase 3 registrational trial in PWS, pending successful completion of . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
December 11, 2025

Other Articles